骨质疏松随机对照试验安慰剂组脱落率的Meta分析及其对临床实践中抗骨质疏松药物反安慰剂相关停药的意义
该Meta分析检索1993年1月至2022年3月双盲随机对照试验,纳入44项试验共16460例安慰剂治疗患者,发现双膦酸盐和SERM试验中反安慰剂脱落率均为8%,且双膦酸盐试验中入组≥65岁患者的研究脱落率(11%)高于入组较年轻患者的研究(6%)。作者认为反安慰剂可能贡献于临床实践中的治疗中断,尤其老年患者,需努力识别和减少反安慰剂效应。
要点
- 44项试验16460例安慰剂患者中,反安慰剂脱落率平均为8%。
- 双膦酸盐试验中≥65岁患者研究脱落率11%,高于较年轻患者研究的6%(p=0.001)。
- 患者性别、给药间隔、发表年份或骨质疏松严重程度对反安慰剂脱落无影响。
核心结论
- 在双膦酸盐和SERM试验中,近1/10接受安慰剂的骨质疏松患者发生导致脱落的不良事件,提示反安慰剂贡献于临床实践中的治疗中断。
- 作者认为需努力识别和减少反安慰剂效应,尤其老年患者。
研究设计与样本
- 检索MEDLINE、EMBASE、SCOPUS和Cochrane数据库,纳入1993年1月至2022年3月发表的所有双盲抗骨质疏松药物试验中安慰剂组因报告不良事件脱落的数据。
- 仅分析双膦酸盐和选择性雌激素受体调节剂(SERM)数据,Prospero注册号CRD42020212843,共提取44项试验数据。
主要发现
- 16460例安慰剂治疗患者中,双膦酸盐汇总反安慰剂脱落率为8%(平均0.08,范围0.01-0.27,95%CI 0.06-0.10),SERM为8%(平均0.08,范围0.03-0.15,95%CI 0.05-0.13)。
- 双膦酸盐试验中入组≥65岁患者的研究(n=18)反安慰剂脱落率为11%(平均0.11,95%CI 0.08-0.13),高于入组较年轻患者的研究(n=18)的6%(平均0.06,95%CI 0.05-0.08),p=0.001。
- 患者性别、给药间隔、发表年份或骨质疏松严重程度对反安慰剂脱落无影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Dropout from placebo arms in randomized-controlled trials is a surrogate for nocebo responses, resulting from patients' negative expectations to treatment. Among 16,460 placebo-treated patients in oral anti-osteoporotic drug trials, nocebo dropouts were 8% on average, being higher in older patients. This implies that nocebo may contribute to the osteoporosis treatment gap in clinical practice. PURPOSE: Osteoporosis is a common disease requiring long-term treatment. Despite the availability of effective anti-osteoporotic drugs, adherence to treatment is low. Nocebo, a behavior mostly related to the negative expectations to a certain treatment, decreases adherence and negatively affects treatment outcomes and health-related care costs in chronic diseases. Since in double-blind placebo-controlled randomized trials any unfavorable outcome leading to discontinuation in placebo arms is considered as nocebo, we aimed to investigate the size of nocebo response in patients participating in osteoporosis trials. METHODS: We searched MEDLINE, EMBASE, SCOPUS, and Cochrane databases for dropouts due to reported adverse events in the placebo arms (nocebo dropouts) in all double-blind trials investigating anti-osteoporotic drugs published between January 1993 and March 2022. Only data on bisphosphonates and selective estrogen receptor modulators (SERMs) were analyzed (Prospero registration number CRD42020212843). RESULTS: Data from 44 trials were extracted. In 16,460 placebo-treated patients, the pooled nocebo-dropout was 8% both for bisphosphonates (average: 0.08; range 0.01-0.27; 95%CI 0.06-0.10) and SERMs (average: 0.08; range 0.03-0.15; 95%CI 0.05-0.13). Nocebo-dropouts were higher in bisphosphonate trials enrolling individuals ≥ 65 years (11%) (n = 18) compared to trials enrolling younger individuals (6%) (n = 18) (average: 0.11; 95%CI 0.08-0.13 vs. average: 0.06; 95%CI 0.05-0.08, respectively, p = 0.001). Participants' sex, dosing-intervals, publication year, or severity of osteoporosis had no impact on the nocebo-dropouts. CONCLUSION: Almost 1 in 10 osteoporosis patients receiving placebo in trials of bisphosphonates and SERMs experiences AEs leading to dropout, implying that nocebo contributes to treatment-discontinuation in clinical practice. Efforts to identify and minimize nocebo, especially in older patients, are warranted.
引用
- Kravvariti E, Kasdagli MI, Diomatari KM, et al. Meta-analysis of placebo-arm dropouts in osteoporosis randomized-controlled trials and implications for nocebo-associated discontinuation of anti-osteoporotic drugs in clinical practice. Osteoporos Int. 2023. PMID: 36596944. doi:10.1007/s00198-022-06658-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。